Cargando…
A Multi-Center, Real-World Study of Chidamide for Patients With Relapsed or Refractory Peripheral T-Cell Lymphomas in China
Chidamide has demonstrated significant clinical benefits for patients with relapsed/refractory (R/R) PTCL in previous studies. This multi-center observational study was aimed to evaluate the objective response rate (ORR), overall survival (OS), and safety of chidamide. From February 2015 to December...
| Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Frontiers Media S.A.
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8602952/ https://www.ncbi.nlm.nih.gov/pubmed/34804937 http://dx.doi.org/10.3389/fonc.2021.750323 |
| _version_ | 1784601671939129344 |
|---|---|
| author | Liu, Weiping Zhao, Donglu Liu, Ting Niu, Ting Song, Yongping Xu, Wei Jin, Jie Cai, Qingqing Huang, Huiqiang Li, Zhiming Hou, Ming Zhang, Huilai Zhou, Jianfeng Hu, Jianda Shen, Jianzhen Shi, Yuankai Yang, Yu Zhang, Liling Zhao, Weili Ding, Kaiyang Qiu, Lugui Tan, Huo Zhang, Zhihui Liu, Lihong Wang, Jinghua Xu, Bing Zhou, Hui Gao, Guangxun Xue, Hongwei Bai, Ou Feng, Ru Huang, Xiaobing Yang, Haiyan Yan, Xiaojing Zeng, Qingshu Liu, Peng Li, Wenyu Mao, Min Su, Hang Wang, Xin Xu, Jingyan Zhou, Daobin Zhang, Hongyu Ma, Jun Shen, Zhixiang Zhu, Jun |
| author_facet | Liu, Weiping Zhao, Donglu Liu, Ting Niu, Ting Song, Yongping Xu, Wei Jin, Jie Cai, Qingqing Huang, Huiqiang Li, Zhiming Hou, Ming Zhang, Huilai Zhou, Jianfeng Hu, Jianda Shen, Jianzhen Shi, Yuankai Yang, Yu Zhang, Liling Zhao, Weili Ding, Kaiyang Qiu, Lugui Tan, Huo Zhang, Zhihui Liu, Lihong Wang, Jinghua Xu, Bing Zhou, Hui Gao, Guangxun Xue, Hongwei Bai, Ou Feng, Ru Huang, Xiaobing Yang, Haiyan Yan, Xiaojing Zeng, Qingshu Liu, Peng Li, Wenyu Mao, Min Su, Hang Wang, Xin Xu, Jingyan Zhou, Daobin Zhang, Hongyu Ma, Jun Shen, Zhixiang Zhu, Jun |
| author_sort | Liu, Weiping |
| collection | PubMed |
| description | Chidamide has demonstrated significant clinical benefits for patients with relapsed/refractory (R/R) PTCL in previous studies. This multi-center observational study was aimed to evaluate the objective response rate (ORR), overall survival (OS), and safety of chidamide. From February 2015 to December 2017, 548 patients with R/R PTCL from 186 research centers in China were included in the study. Among the 261 patients treated with chidamide monotherapy, ORR was 58.6% and 55 patients (21.1%) achieved complete response (CR). Among the 287 patients receiving chidamide-containing combination therapies, ORR was 73.2% and 73 patients (25.4%) achieved CR. The median OS of all patients was 15.1 months. The median OS of patients receiving chidamide monotherapy and combination therapies was 433 and 463 days, respectively. These results demonstrate a significant survival advantage of chidamide treatments as compared with international historical records. Common adverse effects (AEs) were hematological toxicities. Most AEs in both monotherapy and combined treatments were grade 1–2. No unanticipated AEs occurred. In conclusion, chidamide-based therapy led to a favorable efficacy and survival benefit for R/R PTCL. Future studies should explore the potential advantage of chidamide treatment combined with chemotherapy. |
| format | Online Article Text |
| id | pubmed-8602952 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2021 |
| publisher | Frontiers Media S.A. |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-86029522021-11-20 A Multi-Center, Real-World Study of Chidamide for Patients With Relapsed or Refractory Peripheral T-Cell Lymphomas in China Liu, Weiping Zhao, Donglu Liu, Ting Niu, Ting Song, Yongping Xu, Wei Jin, Jie Cai, Qingqing Huang, Huiqiang Li, Zhiming Hou, Ming Zhang, Huilai Zhou, Jianfeng Hu, Jianda Shen, Jianzhen Shi, Yuankai Yang, Yu Zhang, Liling Zhao, Weili Ding, Kaiyang Qiu, Lugui Tan, Huo Zhang, Zhihui Liu, Lihong Wang, Jinghua Xu, Bing Zhou, Hui Gao, Guangxun Xue, Hongwei Bai, Ou Feng, Ru Huang, Xiaobing Yang, Haiyan Yan, Xiaojing Zeng, Qingshu Liu, Peng Li, Wenyu Mao, Min Su, Hang Wang, Xin Xu, Jingyan Zhou, Daobin Zhang, Hongyu Ma, Jun Shen, Zhixiang Zhu, Jun Front Oncol Oncology Chidamide has demonstrated significant clinical benefits for patients with relapsed/refractory (R/R) PTCL in previous studies. This multi-center observational study was aimed to evaluate the objective response rate (ORR), overall survival (OS), and safety of chidamide. From February 2015 to December 2017, 548 patients with R/R PTCL from 186 research centers in China were included in the study. Among the 261 patients treated with chidamide monotherapy, ORR was 58.6% and 55 patients (21.1%) achieved complete response (CR). Among the 287 patients receiving chidamide-containing combination therapies, ORR was 73.2% and 73 patients (25.4%) achieved CR. The median OS of all patients was 15.1 months. The median OS of patients receiving chidamide monotherapy and combination therapies was 433 and 463 days, respectively. These results demonstrate a significant survival advantage of chidamide treatments as compared with international historical records. Common adverse effects (AEs) were hematological toxicities. Most AEs in both monotherapy and combined treatments were grade 1–2. No unanticipated AEs occurred. In conclusion, chidamide-based therapy led to a favorable efficacy and survival benefit for R/R PTCL. Future studies should explore the potential advantage of chidamide treatment combined with chemotherapy. Frontiers Media S.A. 2021-11-04 /pmc/articles/PMC8602952/ /pubmed/34804937 http://dx.doi.org/10.3389/fonc.2021.750323 Text en Copyright © 2021 Liu, Zhao, Liu, Niu, Song, Xu, Jin, Cai, Huang, Li, Hou, Zhang, Zhou, Hu, Shen, Shi, Yang, Zhang, Zhao, Ding, Qiu, Tan, Zhang, Liu, Wang, Xu, Zhou, Gao, Xue, Bai, Feng, Huang, Yang, Yan, Zeng, Liu, Li, Mao, Su, Wang, Xu, Zhou, Zhang, Ma, Shen and Zhu https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
| spellingShingle | Oncology Liu, Weiping Zhao, Donglu Liu, Ting Niu, Ting Song, Yongping Xu, Wei Jin, Jie Cai, Qingqing Huang, Huiqiang Li, Zhiming Hou, Ming Zhang, Huilai Zhou, Jianfeng Hu, Jianda Shen, Jianzhen Shi, Yuankai Yang, Yu Zhang, Liling Zhao, Weili Ding, Kaiyang Qiu, Lugui Tan, Huo Zhang, Zhihui Liu, Lihong Wang, Jinghua Xu, Bing Zhou, Hui Gao, Guangxun Xue, Hongwei Bai, Ou Feng, Ru Huang, Xiaobing Yang, Haiyan Yan, Xiaojing Zeng, Qingshu Liu, Peng Li, Wenyu Mao, Min Su, Hang Wang, Xin Xu, Jingyan Zhou, Daobin Zhang, Hongyu Ma, Jun Shen, Zhixiang Zhu, Jun A Multi-Center, Real-World Study of Chidamide for Patients With Relapsed or Refractory Peripheral T-Cell Lymphomas in China |
| title | A Multi-Center, Real-World Study of Chidamide for Patients With Relapsed or Refractory Peripheral T-Cell Lymphomas in China |
| title_full | A Multi-Center, Real-World Study of Chidamide for Patients With Relapsed or Refractory Peripheral T-Cell Lymphomas in China |
| title_fullStr | A Multi-Center, Real-World Study of Chidamide for Patients With Relapsed or Refractory Peripheral T-Cell Lymphomas in China |
| title_full_unstemmed | A Multi-Center, Real-World Study of Chidamide for Patients With Relapsed or Refractory Peripheral T-Cell Lymphomas in China |
| title_short | A Multi-Center, Real-World Study of Chidamide for Patients With Relapsed or Refractory Peripheral T-Cell Lymphomas in China |
| title_sort | multi-center, real-world study of chidamide for patients with relapsed or refractory peripheral t-cell lymphomas in china |
| topic | Oncology |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8602952/ https://www.ncbi.nlm.nih.gov/pubmed/34804937 http://dx.doi.org/10.3389/fonc.2021.750323 |
| work_keys_str_mv | AT liuweiping amulticenterrealworldstudyofchidamideforpatientswithrelapsedorrefractoryperipheraltcelllymphomasinchina AT zhaodonglu amulticenterrealworldstudyofchidamideforpatientswithrelapsedorrefractoryperipheraltcelllymphomasinchina AT liuting amulticenterrealworldstudyofchidamideforpatientswithrelapsedorrefractoryperipheraltcelllymphomasinchina AT niuting amulticenterrealworldstudyofchidamideforpatientswithrelapsedorrefractoryperipheraltcelllymphomasinchina AT songyongping amulticenterrealworldstudyofchidamideforpatientswithrelapsedorrefractoryperipheraltcelllymphomasinchina AT xuwei amulticenterrealworldstudyofchidamideforpatientswithrelapsedorrefractoryperipheraltcelllymphomasinchina AT jinjie amulticenterrealworldstudyofchidamideforpatientswithrelapsedorrefractoryperipheraltcelllymphomasinchina AT caiqingqing amulticenterrealworldstudyofchidamideforpatientswithrelapsedorrefractoryperipheraltcelllymphomasinchina AT huanghuiqiang amulticenterrealworldstudyofchidamideforpatientswithrelapsedorrefractoryperipheraltcelllymphomasinchina AT lizhiming amulticenterrealworldstudyofchidamideforpatientswithrelapsedorrefractoryperipheraltcelllymphomasinchina AT houming amulticenterrealworldstudyofchidamideforpatientswithrelapsedorrefractoryperipheraltcelllymphomasinchina AT zhanghuilai amulticenterrealworldstudyofchidamideforpatientswithrelapsedorrefractoryperipheraltcelllymphomasinchina AT zhoujianfeng amulticenterrealworldstudyofchidamideforpatientswithrelapsedorrefractoryperipheraltcelllymphomasinchina AT hujianda amulticenterrealworldstudyofchidamideforpatientswithrelapsedorrefractoryperipheraltcelllymphomasinchina AT shenjianzhen amulticenterrealworldstudyofchidamideforpatientswithrelapsedorrefractoryperipheraltcelllymphomasinchina AT shiyuankai amulticenterrealworldstudyofchidamideforpatientswithrelapsedorrefractoryperipheraltcelllymphomasinchina AT yangyu amulticenterrealworldstudyofchidamideforpatientswithrelapsedorrefractoryperipheraltcelllymphomasinchina AT zhangliling amulticenterrealworldstudyofchidamideforpatientswithrelapsedorrefractoryperipheraltcelllymphomasinchina AT zhaoweili amulticenterrealworldstudyofchidamideforpatientswithrelapsedorrefractoryperipheraltcelllymphomasinchina AT dingkaiyang amulticenterrealworldstudyofchidamideforpatientswithrelapsedorrefractoryperipheraltcelllymphomasinchina AT qiulugui amulticenterrealworldstudyofchidamideforpatientswithrelapsedorrefractoryperipheraltcelllymphomasinchina AT tanhuo amulticenterrealworldstudyofchidamideforpatientswithrelapsedorrefractoryperipheraltcelllymphomasinchina AT zhangzhihui amulticenterrealworldstudyofchidamideforpatientswithrelapsedorrefractoryperipheraltcelllymphomasinchina AT liulihong amulticenterrealworldstudyofchidamideforpatientswithrelapsedorrefractoryperipheraltcelllymphomasinchina AT wangjinghua amulticenterrealworldstudyofchidamideforpatientswithrelapsedorrefractoryperipheraltcelllymphomasinchina AT xubing amulticenterrealworldstudyofchidamideforpatientswithrelapsedorrefractoryperipheraltcelllymphomasinchina AT zhouhui amulticenterrealworldstudyofchidamideforpatientswithrelapsedorrefractoryperipheraltcelllymphomasinchina AT gaoguangxun amulticenterrealworldstudyofchidamideforpatientswithrelapsedorrefractoryperipheraltcelllymphomasinchina AT xuehongwei amulticenterrealworldstudyofchidamideforpatientswithrelapsedorrefractoryperipheraltcelllymphomasinchina AT baiou amulticenterrealworldstudyofchidamideforpatientswithrelapsedorrefractoryperipheraltcelllymphomasinchina AT fengru amulticenterrealworldstudyofchidamideforpatientswithrelapsedorrefractoryperipheraltcelllymphomasinchina AT huangxiaobing amulticenterrealworldstudyofchidamideforpatientswithrelapsedorrefractoryperipheraltcelllymphomasinchina AT yanghaiyan amulticenterrealworldstudyofchidamideforpatientswithrelapsedorrefractoryperipheraltcelllymphomasinchina AT yanxiaojing amulticenterrealworldstudyofchidamideforpatientswithrelapsedorrefractoryperipheraltcelllymphomasinchina AT zengqingshu amulticenterrealworldstudyofchidamideforpatientswithrelapsedorrefractoryperipheraltcelllymphomasinchina AT liupeng amulticenterrealworldstudyofchidamideforpatientswithrelapsedorrefractoryperipheraltcelllymphomasinchina AT liwenyu amulticenterrealworldstudyofchidamideforpatientswithrelapsedorrefractoryperipheraltcelllymphomasinchina AT maomin amulticenterrealworldstudyofchidamideforpatientswithrelapsedorrefractoryperipheraltcelllymphomasinchina AT suhang amulticenterrealworldstudyofchidamideforpatientswithrelapsedorrefractoryperipheraltcelllymphomasinchina AT wangxin amulticenterrealworldstudyofchidamideforpatientswithrelapsedorrefractoryperipheraltcelllymphomasinchina AT xujingyan amulticenterrealworldstudyofchidamideforpatientswithrelapsedorrefractoryperipheraltcelllymphomasinchina AT zhoudaobin amulticenterrealworldstudyofchidamideforpatientswithrelapsedorrefractoryperipheraltcelllymphomasinchina AT zhanghongyu amulticenterrealworldstudyofchidamideforpatientswithrelapsedorrefractoryperipheraltcelllymphomasinchina AT majun amulticenterrealworldstudyofchidamideforpatientswithrelapsedorrefractoryperipheraltcelllymphomasinchina AT shenzhixiang amulticenterrealworldstudyofchidamideforpatientswithrelapsedorrefractoryperipheraltcelllymphomasinchina AT zhujun amulticenterrealworldstudyofchidamideforpatientswithrelapsedorrefractoryperipheraltcelllymphomasinchina AT liuweiping multicenterrealworldstudyofchidamideforpatientswithrelapsedorrefractoryperipheraltcelllymphomasinchina AT zhaodonglu multicenterrealworldstudyofchidamideforpatientswithrelapsedorrefractoryperipheraltcelllymphomasinchina AT liuting multicenterrealworldstudyofchidamideforpatientswithrelapsedorrefractoryperipheraltcelllymphomasinchina AT niuting multicenterrealworldstudyofchidamideforpatientswithrelapsedorrefractoryperipheraltcelllymphomasinchina AT songyongping multicenterrealworldstudyofchidamideforpatientswithrelapsedorrefractoryperipheraltcelllymphomasinchina AT xuwei multicenterrealworldstudyofchidamideforpatientswithrelapsedorrefractoryperipheraltcelllymphomasinchina AT jinjie multicenterrealworldstudyofchidamideforpatientswithrelapsedorrefractoryperipheraltcelllymphomasinchina AT caiqingqing multicenterrealworldstudyofchidamideforpatientswithrelapsedorrefractoryperipheraltcelllymphomasinchina AT huanghuiqiang multicenterrealworldstudyofchidamideforpatientswithrelapsedorrefractoryperipheraltcelllymphomasinchina AT lizhiming multicenterrealworldstudyofchidamideforpatientswithrelapsedorrefractoryperipheraltcelllymphomasinchina AT houming multicenterrealworldstudyofchidamideforpatientswithrelapsedorrefractoryperipheraltcelllymphomasinchina AT zhanghuilai multicenterrealworldstudyofchidamideforpatientswithrelapsedorrefractoryperipheraltcelllymphomasinchina AT zhoujianfeng multicenterrealworldstudyofchidamideforpatientswithrelapsedorrefractoryperipheraltcelllymphomasinchina AT hujianda multicenterrealworldstudyofchidamideforpatientswithrelapsedorrefractoryperipheraltcelllymphomasinchina AT shenjianzhen multicenterrealworldstudyofchidamideforpatientswithrelapsedorrefractoryperipheraltcelllymphomasinchina AT shiyuankai multicenterrealworldstudyofchidamideforpatientswithrelapsedorrefractoryperipheraltcelllymphomasinchina AT yangyu multicenterrealworldstudyofchidamideforpatientswithrelapsedorrefractoryperipheraltcelllymphomasinchina AT zhangliling multicenterrealworldstudyofchidamideforpatientswithrelapsedorrefractoryperipheraltcelllymphomasinchina AT zhaoweili multicenterrealworldstudyofchidamideforpatientswithrelapsedorrefractoryperipheraltcelllymphomasinchina AT dingkaiyang multicenterrealworldstudyofchidamideforpatientswithrelapsedorrefractoryperipheraltcelllymphomasinchina AT qiulugui multicenterrealworldstudyofchidamideforpatientswithrelapsedorrefractoryperipheraltcelllymphomasinchina AT tanhuo multicenterrealworldstudyofchidamideforpatientswithrelapsedorrefractoryperipheraltcelllymphomasinchina AT zhangzhihui multicenterrealworldstudyofchidamideforpatientswithrelapsedorrefractoryperipheraltcelllymphomasinchina AT liulihong multicenterrealworldstudyofchidamideforpatientswithrelapsedorrefractoryperipheraltcelllymphomasinchina AT wangjinghua multicenterrealworldstudyofchidamideforpatientswithrelapsedorrefractoryperipheraltcelllymphomasinchina AT xubing multicenterrealworldstudyofchidamideforpatientswithrelapsedorrefractoryperipheraltcelllymphomasinchina AT zhouhui multicenterrealworldstudyofchidamideforpatientswithrelapsedorrefractoryperipheraltcelllymphomasinchina AT gaoguangxun multicenterrealworldstudyofchidamideforpatientswithrelapsedorrefractoryperipheraltcelllymphomasinchina AT xuehongwei multicenterrealworldstudyofchidamideforpatientswithrelapsedorrefractoryperipheraltcelllymphomasinchina AT baiou multicenterrealworldstudyofchidamideforpatientswithrelapsedorrefractoryperipheraltcelllymphomasinchina AT fengru multicenterrealworldstudyofchidamideforpatientswithrelapsedorrefractoryperipheraltcelllymphomasinchina AT huangxiaobing multicenterrealworldstudyofchidamideforpatientswithrelapsedorrefractoryperipheraltcelllymphomasinchina AT yanghaiyan multicenterrealworldstudyofchidamideforpatientswithrelapsedorrefractoryperipheraltcelllymphomasinchina AT yanxiaojing multicenterrealworldstudyofchidamideforpatientswithrelapsedorrefractoryperipheraltcelllymphomasinchina AT zengqingshu multicenterrealworldstudyofchidamideforpatientswithrelapsedorrefractoryperipheraltcelllymphomasinchina AT liupeng multicenterrealworldstudyofchidamideforpatientswithrelapsedorrefractoryperipheraltcelllymphomasinchina AT liwenyu multicenterrealworldstudyofchidamideforpatientswithrelapsedorrefractoryperipheraltcelllymphomasinchina AT maomin multicenterrealworldstudyofchidamideforpatientswithrelapsedorrefractoryperipheraltcelllymphomasinchina AT suhang multicenterrealworldstudyofchidamideforpatientswithrelapsedorrefractoryperipheraltcelllymphomasinchina AT wangxin multicenterrealworldstudyofchidamideforpatientswithrelapsedorrefractoryperipheraltcelllymphomasinchina AT xujingyan multicenterrealworldstudyofchidamideforpatientswithrelapsedorrefractoryperipheraltcelllymphomasinchina AT zhoudaobin multicenterrealworldstudyofchidamideforpatientswithrelapsedorrefractoryperipheraltcelllymphomasinchina AT zhanghongyu multicenterrealworldstudyofchidamideforpatientswithrelapsedorrefractoryperipheraltcelllymphomasinchina AT majun multicenterrealworldstudyofchidamideforpatientswithrelapsedorrefractoryperipheraltcelllymphomasinchina AT shenzhixiang multicenterrealworldstudyofchidamideforpatientswithrelapsedorrefractoryperipheraltcelllymphomasinchina AT zhujun multicenterrealworldstudyofchidamideforpatientswithrelapsedorrefractoryperipheraltcelllymphomasinchina |